ClinicalTrials.gg
Drug

GS-621763 clinical trials

Also written VV116 and JT001.

studies test it
16
open now
0
in phase 3
5
first study started
2021

How each study uses GS-621763 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Deuremidevir Hydrobromide Tablets
3
Deuremidevir Hydrobromide for Suspension
2
VV116 400mg Group
2

Development codes

VV116
9
JT001
7

Studies by the year they started

16 studies that test it; most in 2022 (5)

Studies that test GS-621763, by start year
YearStudies
20214
20225
20235
20242

By phase

A phase 1/2 study counts in both.

Phase 1
10
Phase 2
2
Phase 3
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 16 · Other 0

Vigonvita Life Sciences (7) · Shanghai Vinnerna Biosciences Co., Ltd. (7) · Shanghai JunTop Biosciences Co., LTD (1) · Jeil Pharmaceutical Co., Ltd. (1)

Studies

Open first, then newest update. How each study uses GS-621763 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 16

Codes

What other systems call GS-621763 · ClinicalTrials.gg INT001875

Also registered as deuremidevir hydrobromide (UNII P4L9Q2T94L) and jt-001 (UNII 43K4X7JG75).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.